Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)

SIMPLE SUMMARY: Depatux-M is an antibody-drug conjugate against activated EGFR. The efficacy and tolerability of the Depatux-M and temozolomide combination in recurrent glioblastoma patients were recently analyzed in the INTELLANCE-2/EORTC 1410 phase 2 trial. Despite the trial was negative, it showe...

Description complète

Détails bibliographiques
Auteurs principaux: Padovan, Marta, Eoli, Marica, Pellerino, Alessia, Rizzato, Simona, Caserta, Claudia, Simonelli, Matteo, Michiara, Maria, Caccese, Mario, Anghileri, Elena, Cerretti, Giulia, Rudà, Roberta, Zagonel, Vittorina, Lombardi, Giuseppe
Format: Online Article Texte
Langue:English
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199759/
https://www.ncbi.nlm.nih.gov/pubmed/34204877
http://dx.doi.org/10.3390/cancers13112773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199759/
https://www.ncbi.nlm.nih.gov/pubmed/34204877
http://dx.doi.org/10.3390/cancers13112773

Documents similaires